EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
about
Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinomaDevelopment and novel therapeutics in hepatocellular carcinoma: a reviewHepatocellular carcinoma: From clinical practice to evidence-based treatment protocolsRole of Transcatheter Intra-arterial Therapies for Hepatocellular CarcinomaHow grim is hepatocellular carcinoma?Surveillance for hepatocellular carcinoma.Eag1 channels as potential early-stage biomarkers of hepatocellular carcinomaImage-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspectiveHepatocellular carcinoma: A comprehensive reviewDiagnostic accuracy of gadoxetic acid-enhanced MR for small hypervascular hepatocellular carcinoma and the concordance rate of Liver Imaging Reporting and Data System (LI-RADS).Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAsThe usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot studyRole of local ablative therapy for hepatocellular carcinomaClinically useful diagnostic tool of contrast enhanced ultrasonography for focal liver masses: comparison to computed tomography and magnetic resonance imaging.Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.Optimizing stage of single large hepatocellular carcinoma: A study with subgroup analysis by tumor diameterMajor and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update.New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor ThrombusLong non‑coding RNA AB019562 promotes cell proliferation and metastasis in human hepatocellular carcinoma.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Comparing outcomes of two vascular inflow occlusion techniques and treatment without vascular occlusion during major hepatectomy in patients with Hepatitis B-related hepatocellular carcinomaCombination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinomaClinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).Identification of Zinc Finger, MYM-type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines.Systematic review of ablation techniques for the treatment of malignant or aggressive benign lesions in children.Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy.Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.Familial hepatocellular carcinoma in an endemic area: two case reports.Surgical treatment of intra hepatic recurrence of hepatocellular carcinomaHepatocellular carcinoma surveillance rates in commercially insured patients with noncirrhotic chronic hepatitis B.Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical TreatmentTranscatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?Circulating microRNA-200 Family as Diagnostic Marker in Hepatocellular CarcinomaTimely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy.Clinical guideline SEOM: hepatocellular carcinoma
P2860
Q26740332-3B7A9F9F-6575-4852-8F45-F88766AE8D53Q26752854-CDD80B8E-0882-4BD9-BB34-147053978A68Q26783881-8D2ADD5E-C8BC-433B-AF29-6D00A0123437Q26851627-4A3231F7-65A0-444A-964B-E1F5D998AF23Q27001669-22373D14-8F57-4C43-8A1C-56E63B3A6EA5Q27690269-26C39AC5-3A06-4C3E-924E-D14D91458FACQ28069313-A3994FB1-3C8F-4FED-90D3-CE9CD0C7406BQ28080761-F8A1ECB3-291F-4E4B-A6A0-38985BF1B929Q28087638-7ADBD105-D9E9-484B-819A-16416B24E4DEQ30100967-CE07BBF2-0DF3-499F-AC07-6FAF110B18E4Q30367369-C0C0B333-3A22-4A5D-9346-8BB40B0F1E3AQ30407178-A21017C4-887F-4A9C-8AD7-FD49898248CDQ30417048-700FC865-2F72-40D1-8C6E-10A42CC2925FQ30438199-EEB8BBD2-BD0B-4B65-AF32-CB4DF34E11EFQ33404258-71DB4E73-2127-4E1C-98FA-E8C5D3BFCF41Q33597359-3DD709E6-3426-45EB-A819-06C0A5F01F15Q33617869-EDC9A9CF-CFE1-497A-8326-6BE24E5A8BF2Q33805289-26121624-98C9-4DA8-88C7-513EA34C39ACQ33828043-F0F6D81E-936D-4080-BDAD-298B5B49FF6FQ34137291-ECEF02BC-FEF6-4D9E-9131-F028977C67A8Q34156103-16C58A2A-5091-4D9F-A562-02053B6E5D83Q34169336-D67AD4F4-3D36-44B4-9B6B-90129DEB7B52Q34182483-3B7880A7-E2B5-4DAF-BF2D-4151AA8C1CEBQ34263363-F5D7C12B-1914-44A2-A58A-AD7C9D9352EDQ34362184-61106039-B2B2-4DF7-8B16-996530445F9BQ34826535-435C4859-56BB-4E4F-9F0F-88F451E3CF53Q34911078-DE5D0C5A-F193-48B6-80FC-6E235D6E6232Q35143323-E9BAD121-B52A-4CCA-9B18-A4D342279623Q35167550-25633EE0-DA5F-4960-9677-EB6C80CFF590Q35429876-5C7F2A7E-02C1-4133-A24D-62D3D605C179Q35626757-7E994604-E2C0-4816-93E9-79476F73F369Q35658940-9A1E9DA2-4F8C-418B-A29C-E7AEE8D8EA14Q35765290-202146A7-4604-4FCE-BA47-FC569E604D7CQ35819326-5DAC2388-35AF-4388-819B-7F39363F50D1Q35836354-E84C0828-EFCB-40B0-8168-D44748C49B19Q35867676-4E133822-068F-4C9F-90AF-59ABA7A92234Q35925520-BB342F84-CEE1-42D1-B0A6-222951295344Q36137217-5AFC8FBC-BAE1-4CB8-8CC8-702085D047D1Q36322143-DB71AD86-BB95-48D7-A148-537EA938861FQ36400259-532D750E-CC4C-49F6-BB78-A01EF76D96EB
P2860
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
description
im März 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2012
@uk
name
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
@en
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
@nl
type
label
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
@en
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
@nl
prefLabel
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
@en
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
@nl
P1476
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
@en
P304
P356
10.1016/J.EJCA.2011.12.021
P577
2012-03-01T00:00:00Z